Angiotensin II human

SKU: orb1300121

Description

Angiotensin II is a key vasoactive peptide that elevates blood pressure via AT1R and AT2R receptors, driving vasoconstriction, aldosterone release, and cellular remodeling. It is extensively used in research to establish in vivo models of hypertension and cardiac hypertrophy and for in vitro studies of vascular smooth muscle and endothelial cell function.

Research Area

Cell Biology, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 4474-91-3
• MW: 1046.18
• Purity: 95.00% (May vary between batches)
• Formula: C₅₀H₇₁N₁₃O₁₂
• SMILES: CCC(C)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(CCCN=C(N)N)NC(=O)C(N)CC(O)=O)C(C)C)C(=O)NC(Cc1cnc[nH]1)C(=O)N1CCCC1C(=O)NC(Cc1ccccc1)C(O)=O
• Target: RAAS,Apoptosis
• Solubility: H2O:10.52 mg/mL (10.06 mM);DMSO:< 1 mg/mL (insoluble)

Bioactivity

• Target IC50:
  CHO cells viability:0.52 nM (EC50)|CHO cells viability:1.5 nM
• In Vivo:
  METHODS: To determine insulin action in a human hypertensive mouse model, Angiotensin II (1.1 mg/kg in 0.9% saline) was administered to C57Bl/6J mice using an osmotic minipump for two to four weeks. RESULTS: Blood pressure increased after Angiotensin II treatment. The increase in serum insulin was greater in Angiotensin II-treated mice after glucose administration. Long-term Angiotensin II treatment for four weeks enhanced glucose-stimulated insulin secretion in mice. METHODS: To analyze genotoxic effects in vivo, Angiotensin II (60 ng/kg/min-1 μg/kg/min) was administered using an osmotic minipump to C57Bl/6J mice for four weeks. RESULTS: Angiotensin II increased SBP up to 38 mmHg over control and adversely affected renal function in mice. In the heart, a significant increase in reactive oxygen species formation and double-strand breaks were detected at the highest administered dose. In the kidney, a dose-dependent increase in superoxide formation, double-strand breaks and DNA base modification mutations were observed.
• In Vitro:
  METHODS: Human hepatocellular carcinoma cells (HCC) HepG-2, SMMC-7721, and MHCC97-H were treated with Angiotensin II (1-1000 nM) for 24-72 h. The cell viability was determined using MTT. RESULTS: Angiotensin II induced HCC cell lines to show higher growth in a time- and concentration-dependent manner. METHODS: Neonatal rat cardiomyocytes were treated with Angiotensin II (1 μmol/L) for 5 min-48 h. HMGB1 and IL-6 expression levels were measured by ELISA and RT-qPCR. RESULTS: Angiotensin II enhanced the expression levels of HMGB1 and IL-6 in cardiomyocytes.
• Animal Research:
  (129×C57BL/6) F1 mice, which lack AT1A receptors Angiotensin II used, are fed 10 gm/day gelled 0.25% NaCl diet that contains all nutrients and water. After 28 days of Angiotensin II infusion, hearts are harvested, weighed fixed in formalin, sectioned, and stained with Masson trichrome.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DRVYIHPF, Angiotensin Receptor, Ang II, Angiotensin II human, Angiotensin II, Apoptosis, AT receptor, inhibit, Inhibitor, Hypertensin II

Compound Identifiers

PubChem CID

25476